Cagrilintide

  • 1 lab in 1 country

Outcomes

2

Adverse events

upin humans1

1 study
  1. Cagrilintide increases adverse events in humans.

    Human trialversus placebo

    Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Annals of medicine and surgery (2012)13 Jul 2026

Body weight

downin humans1

1 study
  1. Cagrilintide decreases body weight in humans (MD: -6.08%, MD: -5.89 kg).

    Human trialversus placebo

    Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Annals of medicine and surgery (2012)13 Jul 2026

Trials

30

In trials

All 7
  • Hepatic impairment

    Phase 1Completed1 trial

Development

Companies
  • Novo NordiskPhase 3overweight, obesity

Trial sponsors

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 3Jul 2026: 1Aug 2026: 3Sep 2026: 3Oct 2026: 111 in 12 months